Advances and Prospects in the Treatment of Pancreatic Cancer

Huaiyu Duan\textsuperscript{1,*}, Li Li\textsuperscript{2,*}, Shiming He\textsuperscript{1}

\textsuperscript{1}School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, People’s Republic of China; \textsuperscript{2}Department of Hepatobiliary Pancreatic Oncology, Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Shiming He, Email hesm@ahtcm.edu.cn

Abstract: Pancreatic cancer is a highly malignant and incurable disease, characterized by its aggressive nature and high fatality rate. The most common type is pancreatic ductal adenocarcinoma (PDAC), which has poor prognosis and high mortality rate. Current treatments for pancreatic cancer mainly encompass surgery, chemotherapy, radiotherapy, targeted therapy, and combination regimens. However, despite efforts to improve prognosis, and the 5-year survival rate for pancreatic cancer remains very low. Therefore, it’s urgent to explore novel therapeutic approaches. With the rapid development of therapeutic strategies in recent years, new ideas have been provided for treating pancreatic cancer. This review expositions the advancements in nano drug delivery system, molecular targeted drugs, and photo-thermal treatment combined with nanotechnology for pancreatic cancer. It comprehensively analyzes the prospects of combined drug delivery strategies for treating pancreatic cancer, aiming at a deeper understanding of the existing drugs and therapeutic approaches, promoting the development of new therapeutic drugs, and attempting to enhance the therapeutic effect for patients with this disease.

Keywords: pancreatic cancer, nano drug delivery system, molecular targeted drugs, photo-thermal treatment

Introduction

Pancreatic cancer is a type of digestive system tumor, the incidence of which has been increasing in recent years with a 5-year survival rate close to 10\%.\textsuperscript{1-3} Generally, obesity and diabetes were known as risk factors for this disease, and newly developed or worsened diabetes may be indicative of PDAC. In addition, genetic changes also played a significant role in the development of PDAC.\textsuperscript{4,5} At present, surgery remains the primary treatment for pancreatic cancer. For pancreatic cancer patients who were not eligible for surgical resection, chemotherapy, radiotherapy, and immunotherapy may be considered as treatment options. However, their efficacy was not very satisfactory because of drug resistance.\textsuperscript{6-8} Therefore, it’s pressing to develop novel and more targeted therapies.

With the advancement of modern science and technology, nanoparticles possessed several advantageous characteristics including a large specific surface area, adjustable pore size, high drug loading capacity, excellent biocompatibility, and targeted delivery to tumor tissues with high efficiency.\textsuperscript{9,10} The co-delivery of gemcitabine and cisplatin via nanoparticles could exert a synergistic effect on PDAC.\textsuperscript{11} The matrix of PDAC comprises the extracellular matrix, vascular system, and tumor-associated fibroblasts, which can form into a dense tumor mesenchyme that impedes the drug delivery.\textsuperscript{12} Nano-drug delivery systems have the potential to overcome the tumor interstitial barrier to achieve targeted drug delivery.\textsuperscript{13}

The most frequently overexpressed genes in pancreatic cancer, such as KRAS, CDKN2A, TP53, and SMAD4, which have been identified as potential targets for molecular targeted therapy.\textsuperscript{14} In recent years, molecular targeted therapy for pancreatic cancer has been rapidly developed, including epithelial growth factor receptor inhibitors, and anti-EGFR antibodies, which can block the activation of downstream tyrosine kinase phosphorylation and subsequently inhibit the proliferation of tumor cells. However, these drugs may generate resistance.\textsuperscript{15,16} Pancreatic stellate cells were closely associated with drug-resistance of chemotherapy, which could promote the growth, invasion, and metastasis of tumors.\textsuperscript{17}
The precise release of payloads could be achieved through coupling antibodies with nanoparticles.\textsuperscript{18} The combination of nanotechnology and molecular targeting holds great promise for curing pancreatic cancer in the future.

Photothermal conversion agents or photosensitizers were used in photothermal therapy to absorb energy and generate heat under near-infrared light irradiation of a certain wavelength, thus efficiently eradicating tumor cells. The combination of phototherapy and chemotherapy and phototherapy and gene therapy based on non-viral nanocarriers may be a potential treatment for PDAC.\textsuperscript{19,20} In spite of the dense tumor interstitium in pancreatic tumor tissue that may obstruct the light irradiation and drug delivery, the application of nano-drug delivery technology assisted with near-infrared light can enhance interstitial penetration and improve drug delivery.\textsuperscript{21,22} As photothermal receptors, gold nanomaterials showed unique physical properties that enable them to strongly absorb near-infrared light, thus enhancing the cell permeability and inhibiting the growth of tumor cells significantly.\textsuperscript{23} In plasma photothermal therapy, double peptide-labeled gold nanorods dramatically increase the uptake of pancreatic ductal gland tumor cells and induce the death of pancreatic cancer cells selectively under near-infrared irradiation.\textsuperscript{24} In brief, photothermal therapy provided a new therapeutic strategy for pancreatic cancer patients.

Although there existed many treatments for pancreatic cancer nowadays, huge challenges were inevitable in curing the tumor. Therefore, it’s imperative to develop innovative and effective therapies for this disease. The purpose of this review was to summarize recent advancements in nano-drug delivery systems, molecular targeted therapy, photothermal therapy, and combination drug administration strategies with the hope of providing novel approaches for treating pancreatic cancer.

**The Nano Drug Delivery System**

Nano drug delivery system for pancreatic cancer could mitigate side effects and improve therapeutic efficacy, with the size and unique surface properties of nanoparticles playing a pivotal role in regulating drug release (Figure 1).\textsuperscript{25} Nanoscale drug delivery systems such as liposomes have been widely used in the treatment of pancreatic cancer. Recently, Raza et al

![Delivery of drug:](https://doi.org/10.2147/IJN.S413496)

**Figure 1** Application of nanoparticles in drug delivery for pancreatic cancer. In the treatment of pancreatic cancer, nanoparticle-based delivery of therapeutic drugs could deliver drugs to tumor tissues more specifically and efficiently and reduce side effects of the drugs compared with traditional therapeutic drugs. The surface of nanoparticles modified with specific ligands might precisely target tumor tissue and kill tumor cells.
systematically reviewed the latest research progress in the diagnosis and treatment of pancreatic cancer based on liposomes, providing a therapeutic direction for the treatment of pancreatic cancer.26 In this section, we reviewed mesoporous silica, Poly(lactic-co-glycolic acid), albumin, natural polymers, and exosome-mediated nano-drug delivery systems.

Mesoporous Silica Nanoparticles
Mesoporous silica nanoparticles (MSNs) have been approved by FDA and attracted wide attention in mediating the drug delivery. They were characterized by a large surface area, high drug loading, and the ability to control the release of bioactive substances. Moreover, the targeting ability of functional groups and ligands might be improved if they were modified.27–29 When using folic acid-modified mesoporous silica nanoparticles, specific targeting to the folic acid receptors on tumor cells could improve the therapeutic effect.30,31 In an in situ K-Ras-dependent pancreatic cancer model, delivery of irinotecan via MSNs elicited a more potent anti-tumor immune response compared to single agent irinotecan or the liposomal formulation Onivyde. Furthermore, the concomitant administration of anti-PD-1 could significantly enhance the survival rate of patients with pancreatic cancer.32 ADAM9 was a protease highly expressed in PDAC. A mesoporous silica-modified ADAM9-mediated drug delivery system might effectively target the delivery of paclitaxel, significantly reduce toxic reactions, and improve therapeutic efficacy.33 The sonic hedgehog pathway (SHh) played a crucial role in mediating the crosstalk between cancer cells and stroma. Tarannum et al developed two versions of MSN-based platforms: Cyclopamine mesoporous silica nanoparticles (CyP-MSNs) which were rich in SHh inhibitors, and PEG-Gem-cisPt-MSNs, composed of chemotherapy drugs gémcitabine and cisplatin, that could reduce tumor matrix and ameliorate the curative effect of PDAC.34

As a promising nano-drug delivery platform, MSNs facilitated drug accumulation in tumor cells while reducing the toxic side effects.35 Therefore, the MSNs-mediated nano-drug delivery system represented a highly promising strategy for the treatment of pancreatic cancer.

The Poly (Lactic-Co-Glycolic Acid) Nanoparticles
Poly (lactic-co-glycolic acid) (PLGA) has been approved by the FDA due to its excellent biodegradability, biocompatibility, surface modification capabilities, and controlled release properties.36 When designed as specific targeting molecules, PLGA nanoparticles could encapsulate chemotherapy drugs that specifically target tumor cells for precise drug delivery.37,38 Curcumin was a natural chemical component extracted from the ginger plant, possessing anti-inflammatory and anti-tumor properties.39,40 In-vivo and in-vitro experiments demonstrated that constructing chitosan and polyethylene glycol (PEG) coated PLGA nanoparticles enriched with curcumin might promote apoptosis of pancreatic cancer cells while enhancing cellular uptake when compared to single curcumin.41 In the in situ and ectopic tumor models, PEG-PLGA nanoparticles coated with neutrophilic cell membranes exhibited specific inhibition of the NF-κB signaling pathway, induction of apoptosis in pancreatic cancer cells, and prolonged the survival rates for tumor-bearing mice.42 These biocompatible PLGA NPs with controlled-release properties offered a novel treatment option for pancreatic cancer.

Albumin Nanoparticles
Albumin was classified into human serum albumin and bovine serum albumin, both of which owned the characteristics of non-toxicity, non-immunogenicity, facile preparation, excellent biocompatibility, and active targeting.

Albumin nanoparticles were utilized for the targeted therapy of PDAC by delivering pre-drug β-lap, nab-(pro-β-lap), with experimental results demonstrating its high safety and anti-tumor efficacy.43 Albendazole was encapsulated in 100 nm-diameter nanoparticles which were conjugated with bovine serum albumin and polycaprolactone (PCL). Experiments showed that 100 nm BSA-PCL nanoparticles could accurately and effectively deliver albendazole to pancreatic multicellular tumor spheroids, which revealed the potential application prospect of BSA-PCL nanoparticles as targeted delivery vectors for albendazole in treating pancreatic cancer.44 To inhibit the tumor microenvironment, hydrophobic celestrol and hydrophilic 1-methyltryptophan were encapsulated in cationic albumin nanoparticles coated with hyaluronic acid. Experiments indicated that these nanoparticles could penetrate into the tumor tissue of mouse xenograft models, accumulate within the tumors, and gradually strengthen to significantly inhibit tumor growth in nude mice.45 Additionally, small-sized albumin nanoparticles containing immune checkpoint inhibitors were encapsulated in size-adjustable thermal fibrosis and fibrosis matrix-sensitive liposomes (HSA-BMS@CAP-ILTSL). The two-pronged treatment significantly enhanced the immunotherapy effect of
pancreatic cancer. Therefore, the utilization of albumin-based nanoparticles presented a highly promising approach for targeted drug delivery.

**Natural Polymers**

The application of nanoparticles prepared from natural polymers in the treatment of pancreatic cancer has garnered extensive attention. Marine-derived polymers have emerged as a viable alternative to certain inorganic materials, offering enhanced safety profiles. Fucoidan was a naturally active polysaccharide extracted from brown algae, which exhibited pharmacological effects such as antibacterial, antiviral, and anticancer activities, which could directly inhibit the signal pathway related to cell proliferation, induce cell apoptosis, and suppress cell migration and invasion. Moreover, it had a strong ability to kill pancreatic cancer cells. To enhance the anti-pancreatic cancer activity of the polymer, a novel fucoidan nanoparticle solution was prepared from a novel fucoidan polymer, which dramatically inhibited the proliferation, migration, and invasion of pancreatic cancer cells. Quinacrine was currently used as an anticancer agent. Research results showed that fucoidan and lactoferrin could serve as active targeting ligands to fabricate double-targeted nanoparticles containing quinacrine, resulting in a 5.7-fold increase in anti-cancer activity compared to the single-drug approach.

Lignin was a natural polymer with excellent biodegradability and biocompatibility. In the PANC-1 cell line, quinacrine was loaded into lignosulfonate nanoparticles coated with lactoferrin and hyaluronic acid, which restrained the migration and invasion of pancreatic cancer cells while exhibiting no toxicity towards major organs.

**Exosomes**

Exosomes were cell-derived nano-vesicles with a diameter ranging from 30 to 150 nm. Due to their good biocompatibility, stability, low immunogenicity, and other characteristics, exosomes have been widely used as nanocarrier platforms for delivering chemotherapy drugs and nucleic acids. As a form of intercellular communication, exosomes can transport molecular substances into target cells and activate signaling pathways. Exosomes derived from various sources have been widely utilized as drug-delivery vehicles in the treatment of pancreatic cancer (Table 1).

**Molecular Targeted Therapy**

Molecular targeted therapy for pancreatic cancer was mainly carried out based on targeting epidermal growth factor receptor, human epidermal growth factor receptor 2, trophoblast cell-surface antigen 2, and vascular endothelial growth factor. Figure 2 was a schematic diagram of the related pathways involved in molecular targeting strategies for treating tumors. This section discussed the latest research progress of molecular targeting therapy for pancreatic cancer.

**Epidermal Growth Factor Receptor**

Epidermal growth factor receptor (EGFR) belongs to the ERBB family of cell surface receptor tyrosine kinases. It has the ligand-specific extracellular domain, the transmembrane domain, and an intracellular domain with tyrosine kinase activity. Upon binding to its specific ligand EGF, EGFR can form into homologous or heterodimeric complexes that activate the receptor’s tyrosine kinase through autophosphorylation and trigger the activation of downstream signaling pathways.

**Table 1 Application of Exosome Delivery Drug in the Treatment for Pancreatic Cancer**

<table>
<thead>
<tr>
<th>Origin</th>
<th>Delivery of Substances</th>
<th>Cancer Type</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autologous</td>
<td>Gemcitabine</td>
<td>PC</td>
<td>Significantly inhibited tumor growth</td>
<td>[60]</td>
</tr>
<tr>
<td>PC derived</td>
<td>siPAK4</td>
<td>PC</td>
<td>Inhibited tumor growth and prolong survival</td>
<td>[61]</td>
</tr>
<tr>
<td>Macrophage-derived</td>
<td>Gemcitabine, antagoniR-365</td>
<td>PDAC</td>
<td>Overcame drug resistance and improved survival rate</td>
<td>[62]</td>
</tr>
<tr>
<td>Bone marrow mesenchymal stem cell</td>
<td>Galectin-9, siRNA</td>
<td>PC</td>
<td>Induction of anti-tumor immunity</td>
<td>[63]</td>
</tr>
<tr>
<td>Bone marrow mesenchymal stem cell</td>
<td>Gemcitabine, Paclitaxel</td>
<td>PDAC</td>
<td>Overcame drug resistance</td>
<td>[64]</td>
</tr>
<tr>
<td>Tumor derived re-assembled</td>
<td>Chlorin e6</td>
<td>PC</td>
<td>Inhibition of tumor growth and metastasis</td>
<td>[65]</td>
</tr>
</tbody>
</table>
Currently, therapies targeting EGFR, such as small-molecule tyrosine kinase inhibitors and monoclonal antibodies, have been utilized in the treatment of pancreatic cancer. Small molecule tyrosine kinase inhibitors, such as erlotinib and gefitinib, can selectively bind to overexpressed proteins in tumor cells. They can specifically target the intracellular protein structural domain of EGFR dimer, disrupting adenosine triphosphate (ATP) binding and further inhibiting the phosphorylation of downstream tyrosine kinase. Ultimately, this prevents the growth of tumor cells.

Erlotinib is the sole small-molecule targeted therapy inhibitor approved for treating PDAC. The clinical trials illustrated that the use of erlotinib alone as a monotherapy or in combination with gemcitabine yielded unsatisfactory results. Dacomitinib, an irreversible tyrosine kinase inhibitor with a longer half-life and superior bioavailability than erlotinib, has been shown to inhibit the proliferation of PDAC cells and induce apoptosis by suppressing the expression of FOXM1, aurora kinase B and cyclin B1. Canertinib is another irreversible EGFR inhibitor, which not only inhibits tyrosine phosphorylation but also enhances ubiquitination, and ultimately reduces the proliferation, survival, and migration of pancreatic cancer cells by affecting EGFR family proteins and thereby down-regulating MUC4 mucins.

Monoclonal antibodies, such as cetuximab, prevent the formation of dimer and inhibit tyrosine kinase activation, ultimately suppressing tumor cell growth. In the K-Ras-mutated pancreatic cancer, cetuximab was conjugated with MMAE to form an antibody conjugated (CTX-MMAE), which specifically targeted EGFR and inhibited tumor growth. As shown in Table 2, cetuximab-based treatment for pancreatic cancer has been widely used.
Human Epidermal Growth Factor Receptor 2

Human epidermal growth factor receptor 2 (HER2), also known as ERBB-2, has been highly expressed in pancreatic cancer, which is a ligand-independent receptor tyrosine kinase encoded by proto-oncogenes that triggers a cascade reaction to promote cell proliferation, survival, and migration. Although the combination of HER2 monoclonal antibody trastuzumab and capecitabine has shown promising drug resistance in Phase II clinical trials for pancreatic cancer, it has not yielded satisfactory results in terms of the progression-free survival (PFS) and overall survival (OS). In metastatic pancreatic cancer, the efficacy of cetuximab combined with trastuzumab is superior to that of trastuzumab combined with erlotinib. However, the triple therapy consisting of trastuzumab, gemcitabine, and erlotinib has demonstrated safety and efficacy in terms of PFS and OS. The combination of trastuzumab with other inhibitors has presented a promising prospect for the treatment of pancreatic cancer.

Trophoblast Cell-Surface Antigen 2

Trophoblast cell-surface antigen 2 (TROP2), a transmembrane glycoprotein, is overexpressed in pancreatic cancer and plays a crucial role in the proliferation, migration, and invasion of tumor cells through modulating multiple signaling pathways. Antibody-drug conjugates represented a novel antitumor agent that targeted cancer cells precisely by covalent linkage of cytotoxic drugs to monoclonal antibodies. Sacituzumab govitecan is a monoclonal antibody-drug conjugate that specifically targets TROP2. It consists of a human anti-trop2 monoclonal antibody and SN-38, an active metabolite of irinotecan. IMMU-132 has a significant inhibitory effect on TROP2-overexpressed tumors. In another study, TROP2 Fab-DOX was conjugated with doxorubicin and anti-TROP2 Fab antibody, which exhibit potent antitumor activity against pancreatic cancer in vitro and in vivo. hIMB1636 is a humanized monoclonal antibody targeting TROP2 with high affinity. In a pancreatic cancer model, Cu/177Lu-labeled hIMB1636 demonstrated strong antitumor activity against TROP2-overexpressing tumors.

Vascular Endothelial Growth Factor

The vascular endothelial growth factor (VEGF) family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, and other members, which can bind to the tyrosine kinase receptor VEGFR. The overexpression of VEGF-C in cancer is associated with lymphatic vessel invasion and metastasis, which can be detected in 80% of advanced PDAC. A novel circRNA (circNFI81) may down-regulate the expression of VEGF-C by inhibiting PI3K/Akt pathway; consequently, it inhibits the formation and metastasis of PDAC lymphatic vessels. Bevacizumab, a monoclonal antibody targeting VEGF, has been widely utilized in a variety of tumors. In the Phase III clinical trial of patients with advanced pancreatic cancer treated with the traditional drug gemcitabine, no significant improvement was observed in median PFS. However, when gemcitabine was combined with the double-targeted drugs cetuximab and bevacizumab, the median PFS was significantly improved. On the contrary, the incidence of adverse reactions also increased. Cediranib, a pan-VEGF receptor inhibitor, effectively suppresses the migration and invasion of PDAC cells by downregulating EMT markers ZEB1, N-cadherin, and Snail. Moreover, it synergistically enhances the growth inhibition and apoptosis of PDAC cells when combined with gemcitabine and paclitaxel.
Other

Glycogen synthase kinase 3β (GSK3β) is a highly conserved serine/threonine kinase that regulates cell cycle progression and signal transduction, and its overexpression is closely related to the occurrence and drug resistance of PDAC.\textsuperscript{104,105} Bruceine A inhibited the growth and induced the apoptosis of human pancreatic cancer cells by restraining the PFKFB4/GSK3β-mediated glycolysis pathway.\textsuperscript{106} 9-ING-41 is a novel GSK3β inhibitor which significantly enhances the sensitivity of gemcitabine by regulating the TopBP1/ATR/Chk1 DNA damage response mediated pathway.\textsuperscript{107} Some synthetic topological analogues could induce cell apoptosis by suppressing the phosphorylation of GSK3β in PANC-1 cells.\textsuperscript{108} Long non-coding RNA taurine up-regulated gene 1 (TUG1) was overexpressed in PDAC tissues. In PDAC xenograft mice, the combination of TUG1-specific drug delivery system (TUG1-DDs) and 5-fluorouracil (5-FU) displayed a synergistic effect on chemotherapy compared to 5-FU alone.\textsuperscript{109} MDM2 or NFAT1 oncogenes are often overexpressed in pancreatic cancer, and the use of lead compound MA242 can bind these two genes and induce protein degradation. MA242 can inhibit the growth and metastasis of pancreatic cancer when it’s used alone or combined with gemcitabine.\textsuperscript{110} Activation and overexpression of proto-oncogene tyrosine-protein kinase SRC (SRC) can promote the progression of PDAC. Its inhibitor dasatinib has been shown to effectively inhibit the self-renewal and cloning ability in PDAC.\textsuperscript{111} When combined with erlotinib, the SRC/EGFR inhibitor (dasatinib) could suppress the STAT3 activity, overcome the resistance of gemcitabine, remodel the tumor matrix, and improve the overall survival in mouse models of PDAC.\textsuperscript{112}

Photothermal Therapy

Photothermal therapy (PTT) based on nanotechnology provides promising treatment strategies for pancreatic cancer. Figure 3 illustrates the application of nanotechnology combined with photothermal therapy in treating pancreatic cancer.\textsuperscript{113} Table 3 summarizes the use of photothermal therapy combined with chemotherapy for pancreatic cancer. This section specifically summarized the various combinations of photothermal therapy and other therapies for pancreatic cancer.

Figure 3 Schematic diagram of photothermal treatment for pancreatic cancer. The photothermal agents were administered intravenously or locally. The permeability and retention effect (EPR) might be enhanced by nanotechnology, then the photothermal agents accumulated in the tumor selectively. By locally irradiating the tumor tissue with specific wavelengths of light, the PTT reagent was transformed from the ground state into an excited state, which induced the thermal damage and leads to the tumor death after firing.
Photothermal Therapy Combined with Gene Therapy

The mutation of K-Ras is prevalent in pancreatic cancer. A synergistic therapy utilizing reduced oxidized graphene @gold nanostars and crosslinked with folic acid was combined with a gene targeting G12V mutation of K-Ras. The result illustrated that the combination of photothermal and gene had a significant anti-cancer effect on tumor-bearing mice of pancreatic cancer. Multifunctional single-layer oxidized graphene nanosheets could co-delivery HDAC1 and K-Ras siRNAs to induce gene silence, resulting in significant anti-pancreatic cancer efficacy when combined with near-infrared photo hyperthermia. When doxorubicin and siRNA were co-carried by graphene quantum dots and biodegradable charged polyester vectors, the release of both agents might be triggered through a photothermal effect under laser irradiation. The anticancer activity of this nano-complex would be greatly enhanced.

Photothermal Therapy Combined with Immunotherapy

Immunotherapy is considered as a promising approach for treating pancreatic cancer, including the use of immune checkpoint inhibitors, therapeutic vaccines, engineered T cells, etc. However, certain challenges also exist in immunotherapy, such as autoimmune response and cytokine syndrome. The combination of immunotherapy and other treatments may regulate the immune responses of tumor cells and produce synergistic therapeutic effects. In the treatment of pancreatic cancer with photothermal therapy and local immune adjuvant, 75% of subcutaneous tumors in mice were observed to completely regress, and accompanied by an increase in T cell count that triggered tumor-specific immune memory. The combination of DSPE-PEG and indocyanine green coating on amorphous ferric oxide nanoparticles loaded with imiquimod, followed by ion-assisted MRI-guided interventional photothermal therapy (IPTT), could induce in situ death of the immunogenic cells and trigger powerful anti-tumor immunity through local IPTT treatment. N/PGEM/dp-5 and N/PGEM/dp-16, which were polydopamine (dp) coated with gemcitabine and NLG919 nanoparticles and had a thick dp coated layer, exhibited dramatic enhancement in inhibiting pancreatic cancer when combined with laser irradiation. This provides a promising approach for designing more effective nanoparticle-based immunochemical photothermal therapy for both early-stage and advanced metastatic tumors.

Others

Photothermal therapy, when combined with other therapies such as radiotherapy, can not only overcome the resistance of pancreatic tumors to radiation, but also increase the oxygen levels within tumors and regulate the tumor microenvironment, providing a new strategy for curing pancreatic cancer. A semiconducting polymer nano-radiopharmaceutical labeled with $^{177}$Lu ($^{177}$Lu-SPN-GIP) that possessed photothermal effects has been shown to inhibit the growth of tumor stem cells.
reverse the epithelial-mesenchymal transition (EMT), and decrease the side effects of radiopharmaceutical drugs. A photothermal-based nanoparticle, consisting of anti-urokinase plasminogen activator receptor (uPAR), polyethylene (PEG), and indocyanine green-modified gold nanocapsules, which could improve the median survival rate of complete ablation by 25% with a single intervention when combined with iodine-125 (¹²⁵I) interstitial brachytherapy (IBT). The laser could increase the photothermal effect and catalytic capacity of nano-enzymes within the tumor microenvironment. A novel double-enzyme-like active nano-enzyme (PtFe@Fe₃O₄) has demonstrated effective killing of pancreatic tumor cells in an acidic TME.

Under laser irradiation, nano-enzymes with photothermal properties might induce local thermal reactions, deplete GSH, and ultimately trigger apoptosis and ferroptosis in tumor cells. The laser could increase the photothermal effect and catalytic capacity of nano-enzymes within the tumor microenvironment. A novel double-enzyme-like active nano-enzyme (PtFe@Fe₃O₄) has demonstrated effective killing of pancreatic tumor cells in an acidic TME. Photodynamic therapy (PDT) could induce the oxidative stress reaction by photosensitizers, convert photon energy into oxygen molecules and generate reactive oxygen species to effectively eliminate tumor cells. In order to overcome the challenges of hypoxia and heat shock protein hindrance in pancreatic tumor phototherapy, we developed a photosensitizing agent DCTBT with aggregation-induced emission characteristics. This agent was prepared by an amphiphilic polymer modified with EGFR-targeted peptide, which effectively visualized pancreatic cancer and significantly inhibited tumor growth. A novel platform based on gold nanoclusters was employed for confocal laser endoscopy-guided photothermal therapy /photodynamic therapy of PDAC. An enzyme triggered the release of drug 5-ALA and fluorescent dye Cy5.5, resulting in excellent therapeutic effects with minimal side effects.

**Combined Administration Strategy for Pancreatic Cancer**

A combined drug administration strategy for pancreatic cancer offers numerous advantages. For example, it may solve the insufficient drug accumulation in tumor tissues, overcome drug resistance and reduce toxicity.

The co-delivery of nanoparticles and molecular targeted drugs have displayed a synergistic anti-tumor effect. Conjugation of varlitinib with pegylated gold nanoparticles in a controlled-release delivery system alleviated the toxic side effects of the drug while enhancing its efficacy against pancreatic cancer cells. Coupling EGFR ligands with nanoparticles could induce apoptosis and increase the drug uptake capacity in target cells. The GE11 peptide mixed micellar system, targeted at EGFR, achieved accurate drug release in pancreatic tumor tissues and effectively inhibits the growth of pancreatic tumors when delivering gemcitabine and OMe-PS-miR-519c. If EGFR and GE11 peptides self-assembly into amphiphilic peptide nanoparticles with high encapsulation rates and relatively stable properties, they could co-deliver gemcitabine and olaparib to suppress tumor growth and decrease toxic side effects in a mouse model of pancreatic cancer. When polyethylene glycol-polyethyleneimine-magnetic iron oxide nanoparticles delivered microRNA-21 antisense oligonucleotides and gemcitabine simultaneously, with anti-CD44v6 single chain variable fragment as the targeting moiety, experimental results indicated that co-delivery enhanced the apoptosis and inhibited the growth of pancreatic cancer cells.

Nanoparticles can serve as the carriers of nucleic acid delivery, which can effectively induce cell apoptosis and overcome drug resistance in heterogeneous tumors. PL-1/miR-9 nanoparticles could achieve specific delivery of miR-9, inhibit the expression of eIF5A2, and induce the apoptosis of PDAC cells. Using polymeric nanoparticles containing CXCR4 antagonist to deliver anti-miR-210 and siKRASG12D, the combination therapy displayed improved therapeutic effects, including matrix depletion, decreased immunosuppression, and inhibition of metastasis. A polymer dual-delivery nanoscale device was utilized to co-deliver gemcitabine and microRNA (miR-345), resulting in a combination therapy that reduced the tumor growth and metastasis to distant organs. DODAB: MO (1:2) liposomes were employed as siRNA-lipid complexes prepared by siRNA nano-carriers, which could target FOSL-1 and YAP, leading to significant restrain of tumor growth. Experiments revealed that the AuNRs complex could regulate the release of drugs under 665 nm light treatment, and exhibit synergistic antitumor effects when co-delivering siRNA and adriamycin based on gold nanorods. A novel delivery system for gemcitabine and miR-21 inhibitors, based on dendritic-embedded gold nanoparticles and ultrasonic targeted microbubble destruction (UTMD) technology, showed great potential in the treatment of pancreatic cancer. High-drug-loading AE@NPs prepared by co-loading alantolactone and erlotinib with PLGA nanoparticles restrained the phosphorylation of EGFR and STAT3 simultaneously, activated the ROS-p38 axis, and induced the apoptosis of pancreatic cancer cells, which demonstrated a significant anti-pancreatic cancer effect. The use of membrane-coated carriers for chemotherapy drugs provided a new idea in treating pancreatic cancer. The combination of PLGA NPs coated...
with the macrophage cell membrane and erlotinib might inhibit the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways, which brought about synergistic inhibition of proliferation and angiogenesis in pancreatic cancer cells. This membrane-coated biomimetic nano platform could specifically target pancreatic cancer cells, and dramatically suppress their proliferation and migration when co-delivering gemcitabine, erlotinib, and IRAK4 siRNA.\textsuperscript{162,163}

Magnetic albumin nanosphere containing gemcitabine and the novel cetuximab (C225) was coupled to prepare C225-GEM/MAN, which was used as MRI molecular probes. The results revealed that this dual-targeted thermochemical therapy exhibited the highest targeted killing efficiency on AsPC-1 pancreatic cells.\textsuperscript{164} In addition, mesoporous silica nanoparticles targeted with cetuximab could specifically deliver photosensitized Zinc Phthalocyanine to pancreatic tumor cells with high expression levels of EGFR and selectively kill pancreatic cancer cells.\textsuperscript{165} A photoactivable multi-inhibitor nanoliposomes, based on cabozantinib (XL184), achieved the release of XL184 and inhibit metastatic escape in an in-situ pancreatic tumor model.\textsuperscript{166} Experiment results demonstrated that the nanoPAL-PDT was composed of photo cytotoxic chromophore benzoporphyrin derivative monoacid A (BPD) and bevacizumab, which enhanced drug efficacy by augmenting its cytotoxicity. Moreover, nanoPAL-PDT might dramatically inhibit tumor growth in the in vivo subcutaneous mouse model of pancreatic ductal adenocarcinoma.\textsuperscript{167}

**The Future Prospective**

Pancreatic cancer is a highly malignant tumor that poses significant challenges to treat. While surgical resection remains the primary approach, its efficacy has not improved over time. Chemotherapy represents the first-line therapy for pancreatic cancer. However, drug resistance, dense tumor interstitium and heterogeneity often limit therapeutic outcomes. In the field of medicine, nanomaterials have the potential to overcome biological barriers in drug delivery. The platform for nano-drug delivery can specifically target cancer cells and hypoxic microenvironments within tumors, so as to achieve precise targeting and controlled release of drugs. Albumin-bound paclitaxel nanomedicine (Abraxane\textsuperscript{®}) has been approved by the FDA for the treatment of metastatic pancreatic cancer and is currently the only nanomedicine undergoing clinical trials for treating pancreatic cancer. The development of therapeutic drug delivery based on nanobiotechnology may offer a promising avenue for effective treatment.

Molecular targeted drugs have provided a glimmer of hope for the treatment of pancreatic cancer. Furthermore, molecularly-targeted drugs and nanomaterials that are modified with drugs using nanotechnology or small fragments of antibodies with molecular targeting capabilities have demonstrated encouraging results. Aptamer-functionalized nanomaterials have also made significant strides in the treatment of pancreatic cancer. Although some molecular targeted drugs remain in clinical trials, additional targets and novel nano-drug delivery platforms may be selected to design the optimal drug delivery regimen, therapy advancing the development of individualized therapy for pancreatic cancer in the future.

PTT is a promising cancer therapy, but its effectiveness for deep tumors is limited by the poor tissue penetration of light. Imaging-guided localized regional interventional photothermal therapy offers a new direction for treating pancreatic cancer beyond the body’s surface. When PTT therapy is combined with immunotherapy, gene therapy, and nano-enzyme, important breakthroughs have been achieved in the treatment of pancreatic cancer. However, more consideration of how to overcome the tumor stroma and hypoxia within the tumor microenvironment remains necessary. With the continuous innovation and development of various novel biotechnology, as well as the highly cross-integrated development of medicine, pharmacy, biology, materials science, and other disciplines, we believe that breakthroughs will be achieved in treating pancreatic cancer, so as to benefit a greater number of patients.

**Acknowledgments**

This work was supported by the Anhui University of Chinese Medicine Foundation (2023rcZD003).

**Disclosure**

The authors declare that there are no conflicts of interest.
References


